Altimmune, Inc. (NASDAQ:ALT) Stock Rated “Moderate Buy” by Wall Street Analysts

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.33.

Several brokerages have recently issued reports on ALT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a report on Monday, September 21st. Wall Street Zen upgraded Altimmune from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. HC Wainwright reissued a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Finally, Evercore reaffirmed an “outperform” rating on shares of Altimmune in a report on Wednesday, September 23rd.

Institutional Trading of Altimmune

Large investors have recently made changes to their positions in the business. Quantinno Capital Management LP purchased a new position in Altimmune in the first quarter worth about $33,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Altimmune in the 3rd quarter valued at approximately $36,000. PFG Investments LLC purchased a new position in shares of Altimmune in the 1st quarter worth approximately $42,000. WINTON GROUP Ltd purchased a new position in shares of Altimmune in the 2nd quarter worth approximately $49,000. Finally, North Star Investment Management Corp. increased its position in shares of Altimmune by 112.5% during the 1st quarter. North Star Investment Management Corp. now owns 17,000 shares of the company’s stock valued at $52,000 after purchasing an additional 9,000 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $2.12 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 26.78 and a current ratio of 26.78. The firm has a fifty day moving average price of $2.93 and a 200 day moving average price of $2.96. Altimmune has a fifty-two week low of $2.06 and a fifty-two week high of $6.44. The firm has a market cap of $412.38 million, a price-to-earnings ratio of -2.72 and a beta of 0.06.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. As a group, sell-side analysts expect that Altimmune will post -0.58 earnings per share for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for obesity and liver diseases. The company’s research programs are designed to address metabolic and inflammatory conditions with significant unmet medical needs.

Altimmune’s lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being evaluated for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease.